Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, effective in first-line and subsequent therapies, especially for brain metastases. TRUST-I and TRUST-II trials showed high ...
An expert discusses the 2025 NCCN guideline updates for ROS1-positive non-small cell lung cancer, highlighting the inclusion of taletrectinib and repotrectinib as preferred first-line therapies due to ...
An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
Nuvalent has said it is on course to file for approval of its ROS1 inhibitor zidesamtinib as a lung cancer treatment, although rival Nuvation Bio has beaten it to market. Cambridge, ...
The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell ...
Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients. Dr. Geoffrey Liu, a senior scientist at Princess Margaret ...
Trial initiation follows the recent approval of IBTROZI™ (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer NEW YORK, September 30, 2025--(BUSINESS ...
In summary, the study by Lim et al 8 adds another highly effective agent to the growing roster of TKIs for advanced ROS1-positive NSCLC. However, the study also creates a new dilemma in the field, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback